Tumor Angiogenic Endothelial Cell Targeting by a Novel Integrin-targeted Nanoparticle

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2007 Nov 21

PMID 18019845

Citations 13

Authors

Jianwu Xie

Zhimin Shen

King C P Li

Narasimhan Danthi

Affiliations

Soon will be listed here.

Abstract

Angiogenesis is an important process in cancer growth and metastasis. During the tumor angiogenic process, endothelial cells express various cell surface receptors which can be utilized for molecular imaging and targeted drug delivery. One such protein receptor of interest is the integrin alphav beta3. Our group is involved in the development of molecular imaging probes and drug delivery systems targeting alphav beta3. Based on extensive lead optimization study with the integrin antagonist compounds, we have developed a new generation of integrin alphav beta3 compound (IA) which has superior binding affinity to alphav beta3. Utilizing this IA as a targeting agent, we have developed a novel integrin-targeted nanoparticle (ITNP) system for targ alphav beta3 was observed. These ITNPs also were rapidly taken up by cells that express alphav beta3. The ITNPs accumulated in the angiogenic vessels, after systemic administration in a murine squamous cell carcinoma model. This novel intergrin targeted ITNP platform will likely have an application in targeted delivery of drugs and genes in vivo and can also be used for molecular imaging.

Citing Articles

Effective treatment of intractable diseases using nanoparticles to interfere with vascular supply and angiogenic process.

Hoseinzadeh A, Ghoddusi Johari H, Anbardar M, Tayebi L, Vafa E, Abbasi M Eur J Med Res. 2022; 27(1):232.

PMID: 36333816 PMC: 9636835. DOI: 10.1186/s40001-022-00833-6.

Endothelial Cell Adhesion Molecules- (un)Attainable Targets for Nanomedicines.

Milosevic N, Rutter M, David A Front Med Technol. 2022; 4:846065.

PMID: 35463298 PMC: 9021548. DOI: 10.3389/fmedt.2022.846065.

Biomimetic peptide display from a polymeric nanoparticle surface for targeting and antitumor activity to human triple-negative breast cancer cells.

Bressler E, Kim J, Shmueli R, Mirando A, Bazzazi H, Lee E J Biomed Mater Res A. 2018; 106(6):1753-1764.

PMID: 29424479 PMC: 6035748. DOI: 10.1002/jbm.a.36360.

Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics.

Abdalla A, Xiao L, Ullah M, Yu M, Ouyang C, Yang G Theranostics. 2018; 8(2):533-548.

PMID: 29290825 PMC: 5743565. DOI: 10.7150/thno.21674.

Sodium cholate-enhanced polymeric micelle system for tumor-targeting delivery of paclitaxel.

Zhang X, Wu Y, Zhang M, Mao J, Wu Y, Zhang Y Int J Nanomedicine. 2017; 12:8779-8799.

PMID: 29263668 PMC: 5732553. DOI: 10.2147/IJN.S150196.

References

Eliceiri B, Cheresh D . Role of alpha v integrins during angiogenesis. Cancer J. 2000; 6 Suppl 3:S245-9. View

Ruoslahti E . Specialization of tumour vasculature. Nat Rev Cancer. 2003; 2(2):83-90. DOI: 10.1038/nrc724. View

Sipkins D, Cheresh D, Kazemi M, Nevin L, Bednarski M, Li K . Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med. 1998; 4(5):623-6. DOI: 10.1038/nm0598-623. View

Hunter F, Xie J, Trimble C, Bur M, Li K . Rhodamine-RCA in vivo labeling guided laser capture microdissection of cancer functional angiogenic vessels in a murine squamous cell carcinoma mouse model. Mol Cancer. 2006; 5:5. PMC: 1420324. DOI: 10.1186/1476-4598-5-5. View

Lim E, Danthi N, Bednarski M, Li K . A review: Integrin alphavbeta3-targeted molecular imaging and therapy in angiogenesis. Nanomedicine. 2007; 1(2):110-4. DOI: 10.1016/j.nano.2005.03.008. View

Gutheil J, Campbell T, Pierce P, Watkins J, Huse W, Bodkin D . Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res. 2000; 6(8):3056-61. View

Tucker G . Integrins: molecular targets in cancer therapy. Curr Oncol Rep. 2006; 8(2):96-103. DOI: 10.1007/s11912-006-0043-3. View

Raguse J, Gath H, Bier J, Riess H, Oettle H . Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. Oral Oncol. 2003; 40(2):228-30. DOI: 10.1016/j.oraloncology.2003.08.003. View

STORRS R, Tropper F, Li H, Song C, Sipkins D, Kuniyoshi J . Paramagnetic polymerized liposomes as new recirculating MR contrast agents. J Magn Reson Imaging. 1995; 5(6):719-24. DOI: 10.1002/jmri.1880050617. View

10.

Hood J, Bednarski M, Frausto R, Guccione S, Reisfeld R, Xiang R . Tumor regression by targeted gene delivery to the neovasculature. Science. 2002; 296(5577):2404-7. DOI: 10.1126/science.1070200. View

11.

Winter P, Morawski A, Caruthers S, Fuhrhop R, Zhang H, Williams T . Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation. 2003; 108(18):2270-4. DOI: 10.1161/01.CIR.0000093185.16083.95. View

12.

Duggan M, Duong L, Fisher J, Hamill T, Hoffman W, Huff J . Nonpeptide alpha(v)beta(3) antagonists. 1. Transformation of a potent, integrin-selective alpha(IIb)beta(3) antagonist into a potent alpha(v)beta(3) antagonist. J Med Chem. 2000; 43(20):3736-45. DOI: 10.1021/jm000133v. View

13.

Taga T, Suzuki A, Gonzalez-Gomez I, Gilles F, Stins M, Shimada H . alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer. 2002; 98(5):690-7. DOI: 10.1002/ijc.10265. View

14.

Burnett C, Xie J, Quijano J, Shen Z, Hunter F, Bur M . Synthesis, in vitro, and in vivo characterization of an integrin alpha(v)beta(3)-targeted molecular probe for optical imaging of tumor. Bioorg Med Chem. 2005; 13(11):3763-71. DOI: 10.1016/j.bmc.2005.03.024. View